Download full report with analyst certification and important disclosures
Apr 3 2024, 07:00 IST/BST
Uniphar
Focus on the target
- Sectors : Pharma and healthcare
- Companies : Uniphar
DAVY VIEW
We believe that the headwinds that held back Uniphar’s stock in 2022-2023 are now in the past. The outlook is far more positive. We estimate that achieving its medium-term EBITDA target of €200m would drive a share price of €4.50 in present value. We also see compelling upside in a conservative scenario.
